The following mutations showed the strongest enrichments in specific cancer types: R175H contributed to TP53 mutations with 10% (95% CI: 6–15%) in COAD and 11% (5–18%) in READ compared to 3.7% (3.1–4.4%) in the pan-cancer cohort. This evidence concerns the gene TP53 and cancer.